
He said this was decided at the Covid-19 Vaccine Supply Access Guarantee Special Committee meeting today.
“The use of the AstraZeneca vaccine will continue because clinical data available still points to benefits rather than harms,” he told reporters after a health ministry function.
Adham said the ministry has taken note of reported adverse effects and cases of blood clots among some vaccine recipients.
According to media reports, seven out of 30 AstraZeneca recipients in the UK died after suffering from blood clot.
British health regulators are reportedly considering recommendations to ban the use of AstraZeneca among younger people following concerns about rare cases of blood clotting.
On April 2, Malaysia granted conditional registration approval for the AstraZeneca vaccine supplied through the Covax facility by manufacturer SK Bioscience Co Limited, South Korea.
Adham said Malaysia would also procure 10% of AstraZeneca vaccines from Thailand through direct purchase.
CLICK HERE FOR THE LATEST DATA ON THE COVID-19 SITUATION IN MALAYSIA